Between 1990 and 1993, breast cancer activism became a significant political movement. The issue began to receive extensive media attention, and federal funding for breast cancer research jumped dramatically. Describing the origins of this surge in interest, Maureen Hogan Casamayou attributes it to the emergence of politically potent activism among breast cancer survivors and their supporters. Exploring the creation and development of the National Breast Cancer Coalition (NBCC), she shows how many of its key leaders were mobilized by their own traumatic experiences with the disease and its treatments. Casamayou details the NBCC’s meteoric rise and impressive lobbying efforts, explaining how—in contrast to grassroots movements founded by dedicated individuals—the coalition grew from the simultaneous efforts of a network of women who invested their time, energy, money, and professional skills in the fight for increased funding for breast cancer research. This multiple leadership—or collective entrepreneurialism, says Casamayou—was crucial to the NBCC’s success framing the issue in the minds of the public and policymakers alike.

The commercialization of the breast cancer movement is challenged in this analysis of how breast cancer has been transformed from a stigmatized disease and individual tragedy to a market-driven industry of survivorship.

Hiding Politics in Plain Sight examines the costs of market mechanisms, especially cause marketing, as a strategy for change. Industry and corporate-connected individuals use market mechanisms to brand issues like breast cancer widely, shaping public understanding. But framed as consensus-based social issues rather than contentious political issues, they essentially hide politics in plain sight.

"The Politics of Cancer Revisited," by internationally renowned authority on cancer causes and preventions, Samuel S. Epstein, M.D., backed by meticulous documentation, charges that the cancer establishment remains myopically fixated on damage control--diagnosis and treatment, and basic genetic research with, not always benign, indifference to cancer prevention research and failure of outreach to Congress, regulatory agencies, and the public with scientific information on unwitting exposures to a wide range of avoidable causes of cancer. The National Cancer Institute (NCI) and the American Cancer Society (ACS) are also accused of pervasive conflicts of interest, particularly with the cancer drug industry.

A breast cancer survivor shares her own family history with breast cancer, providing a feminist assessment of the causes, politics, and economics of breast cancer. Explored are such factors as carcinogens and the environment, racial components, domination of the medical field by corporate interests, the issue of breast reconstruction, and other topics. c. Book News Inc.

Scientific Characters chronicles the contests over character, knowledge, trust, and truth in a politically charged scientific controversy that erupted after a 1994 Chicago Tribune headline: "Fraud in Breast Cancer Research: Doctor Lied on Data for Decade." Moving back and forth between news coverage, medical journals, letters to the editor, and oncology pamphlets, Lisa Keränen draws insights from rhetoric, literary studies, sociology, and science studies to analyze the roles of character in shaping the outcomes of the "Datagate" controversy.